Translational Drug Development (TD2)
Janet Howard is a Scheduling and Data Specialist at Translational Drug Development (TD2) since January 2021, previously serving as an In Vivo Research Associate. Prior experience includes positions as a Histology Laboratory Technician at Mayo Clinic, a Laboratory Technician at Upsher-Smith Laboratories, and a Research Technician at American Preclinical Services. Janet also worked as an Analytical Laboratory Technician at Henkel and as an Associate Laboratory Technician at WuXi AppTec. Educational qualifications comprise two Associate’s Degrees in Biotechnology and Molecular Biosciences from Glendale Community College, emphasizing the biology technician and biotechnology laboratory technician fields.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.